<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001080</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 340</org_study_id>
    <secondary_id>11311</secondary_id>
    <nct_id>NCT00001080</nct_id>
  </id_info>
  <brief_title>Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals</brief_title>
  <official_title>Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To ascertain whether the origin of plasma HIV-1-RNA following T cell activation represents&#xD;
      the activation of latently infected cells or an increase in cells permissive for replacing&#xD;
      viral mutants.&#xD;
&#xD;
      The mechanism by which immune stimulation increases circulating levels of HIV-1 is not known.&#xD;
      In particular, it is uncertain whether the transient increase in plasma HIV-1 RNA is due to&#xD;
      enhanced replication of an actively replicating pool of HIV-1, or is due instead to&#xD;
      activation of proviral sequences in previously resting CD4+ cells. One approach to&#xD;
      discriminate these alternatives is a &quot;molecular pulse-chase&quot; experiment. In this approach,&#xD;
      drug resistant mutants would be selected by administration of Lamivudine (3TC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mechanism by which immune stimulation increases circulating levels of HIV-1 is not known.&#xD;
      In particular, it is uncertain whether the transient increase in plasma HIV-1 RNA is due to&#xD;
      enhanced replication of an actively replicating pool of HIV-1, or is due instead to&#xD;
      activation of proviral sequences in previously resting CD4+ cells. One approach to&#xD;
      discriminate these alternatives is a &quot;molecular pulse-chase&quot; experiment. In this approach,&#xD;
      drug resistant mutants would be selected by administration of Lamivudine (3TC).&#xD;
&#xD;
      Twenty subjects without prior 3TC experience will be treated with 3TC for 2 weeks. On day 14,&#xD;
      half of the subjects will receive immunization with both the influenza and pneumococcal&#xD;
      vaccine. 3TC will be discontinued at this time. Patients will be followed for 4 weeks after&#xD;
      the immunization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    as of 4/23/97&#xD;
  </why_stopped>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Virus Vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal Vaccine, Polyvalent (23-valent)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiretroviral therapy, provided the patient has been on the same dose and drugs for&#xD;
             60 days prior to study entry.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented HIV infection.&#xD;
&#xD;
          -  CD4 lymphocyte count of &gt; 300 cells/mm3.&#xD;
&#xD;
          -  One plasma HIV-1 RNA level between &gt;= 20,000 and &lt; 120,000 copies/ml.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Stable antiretroviral therapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
          -  Presence of an AIDS defining opportunistic infection, including Kaposi's sarcoma.&#xD;
&#xD;
          -  Allergy to influenza or pneumococcal vaccine or their components; to egg or egg&#xD;
             products.&#xD;
&#xD;
          -  Unexplained temperature &gt;= 38.5 degrees C for 7 consecutive days within the 30 days&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Concurrent participation in other experimental therapies.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Systemic chemotherapy.&#xD;
&#xD;
          -  Steroids.&#xD;
&#xD;
          -  Corticosteroids.&#xD;
&#xD;
          -  Vaccinations.&#xD;
&#xD;
          -  Any new antiretroviral agents that the patient was not taking at the time of study&#xD;
             entry and not prescribed by the study.&#xD;
&#xD;
          -  Colony stimulating factors including G-CSF or rEPO.&#xD;
&#xD;
          -  Immune modulators/immune based therapies.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy.&#xD;
&#xD;
          -  Transfusion dependent patients.&#xD;
&#xD;
        Patients with any of the following prior conditions are excluded:&#xD;
&#xD;
          -  History of an AIDS defining opportunistic infection, including Kaposi's sarcoma&#xD;
             (except limited cutaneous diseases [&lt; 5 lesions]).&#xD;
&#xD;
          -  History of acute or chronic pancreatitis.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior treatment with 3TC.&#xD;
&#xD;
        Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Treatment with immune modulators.&#xD;
&#xD;
          -  Acute or chronic therapy for recognized infections (eg, influenza, HSV, VZV).&#xD;
&#xD;
        Excluded within 1 year of study entry:&#xD;
&#xD;
        Treatment with an influenza and/or pneumonia vaccine&#xD;
&#xD;
        [AS PER AMENDMENT 1/23/97:&#xD;
&#xD;
          -  influenza vaccine only].&#xD;
&#xD;
        [AS PER AMENDMENT 1/23/97:&#xD;
&#xD;
          -  Excluded within 3 years of study entry:&#xD;
&#xD;
          -  Pneumonia vaccine.]&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuritzkes D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Richman D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Havlir D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphocyte Transformation</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Drug Resistance, Microbial</keyword>
  <keyword>CD4-Positive T-Lymphocytes</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>Influenza Vaccine</keyword>
  <keyword>RNA, Viral</keyword>
  <keyword>Bacterial Vaccines</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Pneumonia, Pneumococcal</keyword>
  <keyword>Viral Load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

